Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gossamer Bio ( (GOSS) ) just unveiled an announcement.
On April 8, 2026, Gossamer Bio disclosed that it received a Nasdaq notice stating its shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days from February 24 through April 7, 2026, though the notice does not trigger immediate delisting. The company has until October 5, 2026, to restore compliance, potentially through measures such as a reverse stock split, but faces the risk of transfer to a lower-tier market or eventual delisting if it cannot satisfy Nasdaq’s rules, outcomes that could weigh on shareholder confidence and trading liquidity.
If Gossamer Bio cannot regain compliance by the October deadline, it may seek an additional 180-day grace period by moving its listing to the Nasdaq Capital Market and demonstrating it can cure the deficiency, subject to Nasdaq staff review. A failure to convince the exchange of its ability to meet listing standards could result in a delisting determination, which the company could appeal, introducing further uncertainty for investors over the stock’s future trading venue and liquidity.
The most recent analyst rating on (GOSS) stock is a Sell with a $0.30 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.
Spark’s Take on GOSS Stock
According to Spark, TipRanks’ AI Analyst, GOSS is a Underperform.
The score is driven down primarily by very weak financial performance (accelerating cash burn, persistent large losses, and negative equity) and a strongly bearish technical backdrop (below all major moving averages with negative MACD). Valuation offers limited support due to negative earnings and no dividend, while the latest corporate event is a meaningful setback after the Phase 3 primary endpoint miss despite some subgroup/secondary positives.
To see Spark’s full report on GOSS stock, click here.
More about Gossamer Bio
Gossamer Bio, Inc. is a biopharmaceutical company whose common stock is listed on the Nasdaq Global Select Market, giving it access to public equity markets and subjecting it to Nasdaq’s continued listing standards, including minimum bid price requirements that can affect its market visibility and investor access.
Average Trading Volume: 16,235,459
Technical Sentiment Signal: Sell
Current Market Cap: $81.53M
See more insights into GOSS stock on TipRanks’ Stock Analysis page.